Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.
Md Abdus SubhanFarzana ParveenHassan ShahSatya Siva Kishan YalamartyJanaína Artem AtaideValdimir P TorchilinPublished in: Cancers (2023)
Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody-drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- randomized controlled trial
- gene expression
- type diabetes
- signaling pathway
- drug delivery
- cancer therapy
- newly diagnosed
- coronary artery disease
- prognostic factors
- patient reported outcomes
- end stage renal disease
- bone marrow
- combination therapy
- endoplasmic reticulum stress
- young adults